Abstract
The identification of a point mutation in the JAK2 gene in most patients with polycythaemia vera (PV) has led to increased insight into the pathogenesis of the disease. The mutation causes cytokine-independent growth and proliferation of haematopoietic precursor cells, leading to erythrocytosis. The JAK2-V617F mutation is present in 65-97% of PV-patients and, when found, is indicative for the disease. Future research will have to show if the mutated gene can serve as a target for specific, antiproliferative therapy
Original language | Dutch |
---|---|
Pages (from-to) | 1784-1787 |
Journal | Nederlands Tijdschrift voor Geneeskunde |
Volume | 151 |
Issue number | 32 |
Publication status | Published - 2007 |